The process of food intake appears to be organized at the cellular level like a relay race: during eating, the baton is ...

Relay Therapeutics was able to report positive interim data from its phase 1 study, using RLY-2608 + fulvestrant. Learn more ...

“We know little about how the brain controls the duration of this consummatory phase. It should neither ... that become ...

Relay Therapeutics (RLAY) has received a new Buy rating, initiated by Goldman Sachs analyst, Salveen Richter. Salveen Richter has given his Buy ...

Relay Therapeutics (NASDAQ:RLAY) is up ~5% in premarket trading after Stifel and HC Wainwright issued bullish notes on the stock following promising interim data on a breast cancer asset. Those ...

Ahead of the readout, Relay identified the 5.5-month progression-free survival (PFS) seen in a study of AstraZeneca’s Truqap as the benchmark for its trial. Monday, Relay reported a median PFS of 9.2 ...

Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human study ...

Private Cloud Compute is an entirely new kind of infrastructure that, Apple’s Craig Federighi tells WIRED, allows your ...

The company said interim data from a Phase I trial of RLY-2608 plus fulvestrant support moving the program into a pivotal study in 2025.

Abstract: A urine collection system includes a urine collection device configured to collect urine discharged from a user and ...

This study presents a valuable finding on the role of the Inferior Colliculus in sensory prediction, cognitive decision-making, and reward prediction. The evidence supporting the claims of the authors ...

[Starts abruptly] biotech analysts here. [Technical Difficulty] to have presenting with us next, Gilead Sciences. Thanks for coming today. We really appreciate it. Maybe just to kick things off, I'll ...